Merrimack Pharmaceuticals Inc. buy marge
Summary
This prediction ended on 08.07.16 with a price of €51.41. The prediction for Merrimack Pharmaceuticals Inc. disappointed with a performance of -16.30%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0.754% | -1.027% | 14.485% | 59.395% |
| iShares Nasdaq 100 | -2.859% | -4.266% | 2.185% | 85.679% |
| iShares Nikkei 225® | 4.946% | 5.736% | 25.355% | 57.349% |
| iShares S&P 500 | -1.254% | -2.357% | 1.146% | 58.964% |
Comments by marge for this prediction
In the thread Merrimack Pharmaceuticals Inc. diskutieren
FDA genehmigt: Die Behandlung von Patienten mit metastasiertem Bauchspeicheldrüsenkrebs!
A speculative pick of the bunch with a small biotech concern called Merrimack Pharmaceuticals, which is at under $7.00 a share, about half its levels earlier this summer. The stock has declined despite the fact the FDA approved Merrimack's main drug candidate MM-398 known by its brand name "Onivyde" , in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy in late October. Onivyde could eventually have $800 million in annual sales which is about equal to Merrimack's current market capitalization.
The company also has several promising compounds "MM-121, MM-141, MM-302" or "shots on goal" in early and mid-stage development as well. Merrimack recently raised $175 million to fund development of these drugs.
Four analysts have price targets on Merrimack in a relatively tight range of $13.00 to $15.00 a share.